



1652

PATENT *JPW*

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: P. Mukerji, et al.

Serial No.: 09/624,670

Filed: July 24, 2000

Title: ELONGASE GENES AND USES  
THEREOF

Attorney Docket No.: 6407.US.P2

Examiner: Ramirez, D.M.

Group Art Unit: 1652

## CERTIFICATE OF MAILING (37 CFR

1.8 (a)): I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Date of Deposit: 5/17/04

*Kimberly A. Iorio*  
\_\_\_\_\_  
Kimberly A. Iorio

TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith for the patent application identified above entitled ELONGASE GENES AND USES THEREOF are the following:

1. Supplemental Information Disclosure Statement (2 Pages), in duplicate;
2. Copy of International Search Report (4 Pages);
3. Form PTO-1449 (1 Page), in duplicate;
4. References as cited on Form PTO-1449 (5 references); and
5. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

Respectfully submitted,  
P. Mukerji, et al.

ABBOTT LABORATORIES  
Customer No.: 23492  
Telephone: (847) 935-1729  
Facsimile: (847) 938-2623

*Cheryl L. Becker*  
\_\_\_\_\_  
Cheryl L. Becker  
Registration No. 35,441  
Attorney for Applicants



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: P. Mukerji , et al.

Serial No.: 09/624,670

Filed: July 24, 2000

Title: ELONGASE GENES AND USES  
THEREOF

Attorney Docket No.: 6407.US.P2

Examiner: Ramirez, D.M.

Group Art Unit: 1652

**CERTIFICATE OF MAILING (37 CFR  
1.8 (a)):**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Date of Deposit: 5/17/04

*Kimberly A. Idorio*  
Kimberly A. Idorio

5/17/04  
Date

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The following information is submitted pursuant to 37 C.F.R. §1.97 and §1.98 in accordance with Applicants' duty of disclosure under 37 C.F.R. §1.56. This submission is not an admission that the documents cited herein are prior art as to the invention claimed. In accordance with 37 CFR §§1.97(g)-(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined by 37 CFR §1.56(a) exists.


Applicants submit herewith Form PTO-1449 listing the references known to them. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Form PTO-1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO-1449 to Applicants. Copies of the references are also enclosed.

Documents listed in this Supplemental Information Disclosure Statement were first cited in an International Search Report, dated April 9, 2004, issued in connection with a related application, PCT Application No. PCT/US03/16863. (A copy of the Search Report has been enclosed for the Examiner's convenience.) This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the International Search Report.

Applicants believe no charge is required for the submission of this Information Disclosure Statement under 37 C.F.R. § 1.97 (b). However, if a fee is determined to be due, authorization to charge Deposit Account No. 01-0025 for any additional filing fees required.

Respectfully submitted,  
P. Mukerji, et al.

ABBOTT LABORATORIES  
Customer No.: 23492  
Telephone: (847) 935-1729  
Facsimile: (847) 938-2623

  
Cheryl L. Becker  
Registration No. 35,441  
Attorney for Applicants



DATE: May 17, 2004

SHEET 1 of 1

FORM PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6407.US.P2	SERIAL NO. 09/624,670
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98 (b))	APPLICANT(S) P. Mukerji, et al.	
	FILING DATE July 24, 2000	GROUP 1652

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	Arita et al., Effect of n-3 and n-6 polyunsaturated fatty acids and their ethylesters on stimuli-dependent superoxide generation in neutrophils. Physicol Chem Phys Med NMR. 2001;33(2):121-32.
	C2	Haban et al., Supplementation with long-chain n-3 fatty acids in non-insulin dependent diabetes mellitus (NIDDM) patients leads to the lowering of oleic acid content in serum phospholipids. Eur J Nutr. 2000 Oct;39(5):201-6.
	C3	Pirich et al., Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients. Thromb Res. 1999 Nov. 1;96(3):219-27.
	C4	Calviello et al., Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: effects on proliferation and apoptosis. Int J Cancer. 1998 Mar 2;75(5):699-705.
	C5	Tardy et al., Priming effect of adrenic acid (22:4(n-6)) on tissue factor activity expressed by thrombin-stimulated endothelial cells. Atherosclerosis. 1992 Jul;95(1):51-8.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE: May 17, 2004

SHEET 1 of 1

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6407.US.P2

SERIAL NO.

09/624,670

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S)

P. Mukerji, et al.

FILING DATE

July 24, 2000

GROUP

1652

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Arita et al., Effect of n-3 and n-6 polyunsaturated fatty acids and their ethylesters on stimuli-dependent superoxide generation in neutrophils. Physiol Chem Phys Med NMR. 2001;33(2):121-32.
C2	Haban et al., Supplementation with long-chain n-3 fatty acids in non-insulin dependent diabetes mellitus (NIDDM) patients leads to the lowering of oleic acid content in serum phospholipids. Eur J Nutr. 2000 Oct;39(5):201-6.
C3	Pirich et al., Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients. Thromb Res. 1999 Nov. 1;96(3):219-27.
C4	Calviello et al., Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: effects on proliferation and apoptosis. Int J Cancer. 1998 Mar 2;75(5):699-705.
C5	Tardy et al., Priming effect of adrenic acid (22:4(n-6)) on tissue factor activity expressed by thrombin-stimulated endothelial cells. Atherosclerosis. 1992 Jul;95(1):51-8.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

